Most Recent Episode
Respiratory GURU Episode 4: Review of asthma biologics in NICE and in development Time: 48:55
Discussion with Professor Adel Mansur who is the lead for the Birmingham Regional Asthma Service about the 4 main current biologics in the asthma NICE guidelines together with discussion of three more novel agents in development that have recently been published. A must listen for anyone reviewing asthma patients, Adel gives a great summary of the underlying mechanisms for these agents, their current use in clinical practice and importantly...how to pronounce them! Papers reviewed are as follows:
Dupilumab https://www.nice.org.uk/guidance/TA751
Mepolizumab https://www.nice.org.uk/guidance/TA671
Benralizumab https://www.nice.org.uk/guidance/TA565
Reslizumab https://www.nice.org.uk/guidance/TA479
Brightling CE, Nair P, Cousins DJ, Louis R, Singh D. Risankizumab in Severe Asthma - A Phase 2a, Placebo-Controlled Trial. N Engl J Med. 2021 Oct 28;385(18):1669-1679. doi: 10.1056/NEJMoa2030880. PMID: 34706172.
Wechsler ME, Ruddy MK, Pavord ID, Israel E, Rabe KF, Ford LB, Maspero JF, Abdulai RM, Hu CC, Martincova R, Jessel A, Nivens MC, Amin N, Weinreich DM, Yancopoulos GD, Goulaouic H. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. N Engl J Med. 2021 Oct 28;385(18):1656-1668. doi: 10.1056/NEJMoa2024257. PMID: 34706171.
Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, Brightling CE, Griffiths JM, Hellqvist Å, Bowen K, Kaur P, Almqvist G, Ponnarambil S, Colice G. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med. 2021 May 13;384(19):1800-1809. doi: 10.1056/NEJMoa2034975. PMID: 33979488.
GUID: Buzzsprout-9927090
Release Date: 21/01/2022, 21:30:00
